In Atrial Fibrillation, SentreHEART Lassos An Advantage
SentreHEART is operating in one of the most promising device spaces in stroke: percutaneous left atrial appendage closure. Unlike early movers, SentreHEART doesn’t leave an implant behind in the heart, and its LARIAT procedure might have unique benefits in addressing not only the stroke risk that comes with atrial fibrillation, but also AF itself.
You may also be interested in...
The American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions released an overview of left atrial appendage occlusion devices, specifically Boston Scientific's Watchman and SentreHEART's Lariat.
Manufacturers are finding it harder to innovate in the vascular interventional devices as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in renal denervation, drug-coated balloons, and renal artery stenting; still there are some promising areas, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.
FDA’s Circulatory System Devices advisory panel voted 13-1 to recommend approval of the firm’s PMA for the Watchman device as an alternative to warfarin therapy for stroke prevention in atrial fibrillation patients for whom long-term anticoagulant therapy is too risky.